Friday, July 21, 2017
News Recap
1) Vosevi Approved in US – Under Review in Canada
Vosevi has just been approved in the USA to treat adults with chronic HCV genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing sofosbuvir, velpatasvir and a new drug, voxilaprevir. Vosevi is the first treatment approved for patients who have been previously treated with DAAs and failed treatment....
The complications include liver cancer, failure, transplantation or death. Consistent medical monitoring is recommended.
Individuals who are treated for hepatitis C virus (HCV) when they have advanced fibrosis or cirrhosis remain at high risk of liver disease progression even after being cured of the virus. Consequently, researchers recommend routine monitoring for this group.
Publishing their findings in the Journal of Hepatology, researchers conducte
SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ -- Hepatocellular carcinoma (HCC) remains one of the cancers growing in frequency and mortality in the United States. Patients with hepatitis C virus (HCV) left untreated will often progress to cirrhosis and HCC. Direct acting antivirals (DAAs) now used to treat patients with HCV have achieved almost universal cure rates. However, the risk of HCC following cure is not clear. Researchers from Houston VA Medical Cent